Precigen, Inc.
PGEN · NASDAQ
Bulios Fair Price
$6.45
18.0% downside
Current Price
$7.87
According to Bulios Fair Price, PGEN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Precigen, Inc. (PGEN) is a biotechnology company focused on the development and commercialization of advanced therapeutic and diagnostic technologies. The company specializes in genome engineering and genetic manipulation, enabling the development of novel drugs and diagnostic tools for the treatment and detection of various diseases. Their technologies include CRISPR-Cas9 and other genome editing tools, gene therapy, immunotherapy, and genetic analysis-based diagnostic tests.
Sector
Healthcare
Industry
Biotechnology
CEO
Helen Sabzevari
Employees
160
Headquarters
Germantown
Upcoming events
Earnings
Upcoming earnings report